Heart Failure Efficacy and Research Trial (HEART) Platform
ConditionHeart Failure
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity of Alberta
About this trial
The Heart Failure Efficacy and Research Trial (HEART) Platform is a multicenter, randomized platform study designed to improve outcomes for patients with heart failure through the simultaneous and sequential evaluation of multiple interventions across the spectrum of heart failure.
Eligibility criteria
Qualifiers
Age ≥18 years (or legal age of majority in participant's country of residence).
State 1: Worsening Heart Failure (WHF): currently hospitalized for acute decompensated heart failure or emergency department patients requiring intravenous therapy for heart failure; OR
State 2: Ambulatory Heart Failure: stable outpatients with established heart failure diagnosis, receiving ongoing HF management and without HF hospitalization within the prior 30 days.
Able and willing to provide written informed consent (or consent via a legally authorized representative, where applicable).
Disqualifiers
Inability to provide informed consent (and no legally authorized representative available when applicable).
Not eligible for assignment to either HEART platform state (State 1 or State 2).
Presence of conditions or circumstances that, in the investigator's opinion, would make study participation unsafe or not feasible (e.g., inability to comply with study procedures or follow-up).
Does not meet the eligibility requirements for any active HEART Platform domain.
Trial design
Treatments tested in this trial
- Domain Intervention(s)
- Control / Standard of Care Comparator
Treatment groups
1,000 Participants
are divided into 2 treatment groupsLocations
Sponsors and collaborators
University of Alberta
Lead sponsor
Canadian VIGOUR Centre
Collaborator
Source ClinicalTrials.gov